vilobelimab   Click here for help

GtoPdb Ligand ID: 11346

Synonyms: CaCP-29 | IFX-1
Compound class: Antibody
Comment: Vilobelimab (IFX-1) is a chimeric IgG4 monoclonal antibody against the terminal complement component, anaphylatoxin C5a. It was developed for potential to treat complement mediated inflammatory diseases. Vilobelimab blocks C5a/C5aR1 signalling in subsets of myeloid-derived suppressor cells (MDSCs) and neutrophils.
No information available.
Summary of Clinical Use Click here for help
Vilobelimab (IFX-1) has advanced to clinical evaluation in difficult to treat inflammatory diseases [5-6,8].
SARS-CoV-2 and COVID-19: In response to the COVID-19 pandemic, vilobelimab was entered into clinical trial, with the purpose of determining potential efficacy of blocking the C5a-C5aR1 axis to limit myeloid infiltration and prevent excessive lung inflammation in COVID-19 patients [2], and early results have been published which support advance to a higher powered Phase 3 study [10].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04333420 Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia Phase 2/Phase 3 Interventional InflaRx GmbH 10
NCT03487276 Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) Phase 2 Interventional InflaRx GmbH 10
NCT03895801 Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Phase 2 Interventional InflaRx GmbH 10
NCT03001622 Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa Phase 2 Interventional InflaRx GmbH 3